187 related articles for article (PubMed ID: 37925761)
1. Venetoclax-based therapy in treatment-naïve and relapsed/refractory acute myeloid leukemia.
Ravindra A; Acharya L; Loeffler B; Mott S; Sutamtewagul G; Dhakal P
Leuk Res; 2023 Dec; 135():107407. PubMed ID: 37925761
[TBL] [Abstract][Full Text] [Related]
2. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
3. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
4. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.
Weng G; Zhang Y; Yu G; Luo T; Yu S; Xu N; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Shao R; Du X; Jin H; Liu Q
J Intern Med; 2023 Mar; 293(3):329-339. PubMed ID: 36284445
[TBL] [Abstract][Full Text] [Related]
5. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.
Stahl M; Menghrajani K; Derkach A; Chan A; Xiao W; Glass J; King AC; Daniyan AF; Famulare C; Cuello BM; Horvat TZ; Abdel-Wahab O; Levine RL; Viny AD; Stein EM; Cai SF; Roshal M; Tallman MS; Goldberg AD
Blood Adv; 2021 Mar; 5(5):1552-1564. PubMed ID: 33687434
[TBL] [Abstract][Full Text] [Related]
6. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
7. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
Graveno ME; Carulli A; Freyer CW; Mangan BL; Nietupski R; Loren AW; Frey NV; Porter DL; Gill SI; Hexner EO; Luger SM; Martin ME; McCurdy SR; Perl AE; Babushok DV; Pratz KW
Leuk Lymphoma; 2022 Jul; 63(7):1645-1650. PubMed ID: 35259056
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Desikan SP; Ravandi F; Pemmaraju N; Konopleva M; Loghavi S; Jabbour EJ; Daver N; Jain N; Chien KS; Maiti A; Montalban-Bravo G; Kadia TM; Macaron W; DeLumpa R; Kwari M; Borthakur G; Short NJ
Acta Haematol; 2022; 145(5):529-536. PubMed ID: 35717939
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.
Jin H; Zhang Y; Yu S; Du X; Xu N; Shao R; Lin D; Chen Y; Xiao J; Sun Z; Deng L; Liang X; Zhang H; Guo Z; Dai M; Shi P; Huang F; Fan Z; Yin Z; Xuan L; Lin R; Jiang X; Yu G; Liu Q
J Hematol Oncol; 2023 Apr; 16(1):42. PubMed ID: 37120593
[TBL] [Abstract][Full Text] [Related]
11. Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.
Weng G; Huang J; An N; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; He X; Jin H; Liu Q; Du X
Cancer Med; 2024 Jan; 13(2):e6885. PubMed ID: 38334500
[TBL] [Abstract][Full Text] [Related]
12. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Todisco E; Papayannidis C; Fracchiolla N; Petracci E; Zingaretti C; Vetro C; Martelli MP; Zappasodi P; Di Renzo N; Gallo S; Audisio E; Griguolo D; Cerchione C; Selleri C; Mattei D; Bernardi M; Fumagalli M; Rizzuto G; Facchini L; Basilico CM; Manfra I; Borlenghi E; Cairoli R; Salutari P; Gottardi M; Molteni A; Martini V; Lunghi M; Fianchi L; Cilloni D; Lanza F; Abruzzese E; Cascavilla N; Rivellini F; Ferrara F; Maurillo L; Nanni J; Romano A; Cardinali V; Gigli F; Roncoroni E; Federico V; Marconi G; Volpi R; Sciumè M; Tarella C; Rossi G; Martinelli G;
Cancer; 2023 Apr; 129(7):992-1004. PubMed ID: 36692409
[TBL] [Abstract][Full Text] [Related]
13. [Clinical Observation of Venetoclax Combined with Demethylating Agents on the Treatment of Relapsed/Refractory Acute Myeloid Leukemia].
Wang Y; Huang SL; Zhang XX; Bian MR; Lin GQ; Si YJ; Zhang B; Wan Y; Wang L; Zhang YM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):327-332. PubMed ID: 37096501
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
Sanber K; Ye K; Tsai HL; Newman M; Webster JA; Gojo I; Ghiaur G; Prince GT; Gondek LP; Smith BD; Levis MJ; DeZern AE; Ambinder AJ; Dalton WB; Jain T
Leuk Lymphoma; 2023 Apr; 64(4):846-855. PubMed ID: 36744656
[TBL] [Abstract][Full Text] [Related]
15. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
Maiti A; DiNardo CD; Qiao W; Kadia TM; Jabbour EJ; Rausch CR; Daver NG; Short NJ; Borthakur G; Pemmaraju N; Yilmaz M; Alvarado Y; Montalbano KS; Wade A; Maduike RE; Guerrero JA; Vaughan K; Bivins CA; Pierce S; Ning J; Ravandi F; Kantarjian HM; Konopleva MY
Cancer; 2021 Nov; 127(22):4213-4220. PubMed ID: 34343352
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
DiNardo CD; Lachowiez CA; Takahashi K; Loghavi S; Xiao L; Kadia T; Daver N; Adeoti M; Short NJ; Sasaki K; Wang S; Borthakur G; Issa G; Maiti A; Alvarado Y; Pemmaraju N; Montalban Bravo G; Masarova L; Yilmaz M; Jain N; Andreeff M; Jabbour E; Garcia-Manero G; Kornblau S; Ravandi F; Konopleva MY; Kantarjian HM
J Clin Oncol; 2021 Sep; 39(25):2768-2778. PubMed ID: 34043428
[TBL] [Abstract][Full Text] [Related]
17. Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.
Weng G; Huang J; He X; Xue T; Yang L; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Jin H; Liu Q; Du X
Ann Hematol; 2023 Dec; 102(12):3369-3381. PubMed ID: 37723307
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M
Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia.
Bouligny IM; Murray G; Doyel M; Patel T; Boron J; Tran V; Gor J; Hang Y; Alnimer Y; Ho T; Zacholski K; Venn C; Wages NA; Grant S; Maher KR
Med Oncol; 2024 Feb; 41(3):80. PubMed ID: 38396145
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
DiNardo CD; Pratz K; Pullarkat V; Jonas BA; Arellano M; Becker PS; Frankfurt O; Konopleva M; Wei AH; Kantarjian HM; Xu T; Hong WJ; Chyla B; Potluri J; Pollyea DA; Letai A
Blood; 2019 Jan; 133(1):7-17. PubMed ID: 30361262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
